Cargando…

Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma

Metastatic pheochromocytoma and paraganglioma (PPGL) are incurable neuroendocrine tumors. The goals of treatment include palliating symptoms and reducing tumor burden. Little is known about the use of radiofrequency ablation (RFA), cryoablation (CRYO), and percutaneous ethanol injection (PEI) to tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohlenberg, Jacob, Welch, Brian, Hamidi, Oksana, Callstrom, Matthew, Morris, Jonathan, Sprung, Juraj, Bancos, Irina, Young, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407137/
https://www.ncbi.nlm.nih.gov/pubmed/30736463
http://dx.doi.org/10.3390/cancers11020195
_version_ 1783401478974603264
author Kohlenberg, Jacob
Welch, Brian
Hamidi, Oksana
Callstrom, Matthew
Morris, Jonathan
Sprung, Juraj
Bancos, Irina
Young, William
author_facet Kohlenberg, Jacob
Welch, Brian
Hamidi, Oksana
Callstrom, Matthew
Morris, Jonathan
Sprung, Juraj
Bancos, Irina
Young, William
author_sort Kohlenberg, Jacob
collection PubMed
description Metastatic pheochromocytoma and paraganglioma (PPGL) are incurable neuroendocrine tumors. The goals of treatment include palliating symptoms and reducing tumor burden. Little is known about the use of radiofrequency ablation (RFA), cryoablation (CRYO), and percutaneous ethanol injection (PEI) to treat metastatic PPGL. We performed a retrospective study of patients age 17 years and older with metastatic PPGL who were treated with ablative therapy at Mayo Clinic, USA, between June 14, 1999 and November 14, 2017. Our outcomes measures were radiographic response, procedure-related complications, and symptomatic improvement. Thirty-one patients with metastatic PPGL had 123 lesions treated during 42 RFA, 23 CRYO, and 4 PEI procedures. The median duration of follow-up was 60 months (range, 0–163 months) for non-deceased patients. Radiographic local control was achieved in 69/80 (86%) lesions. Improvement in metastasis-related pain or symptoms of catecholamine excess was achieved in 12/13 (92%) procedures. Thirty-three (67%) procedures had no known complications. Clavien-Dindo Grade I, II, IV, and V complications occurred after 7 (14%), 7 (14%), 1 (2%), and 1 (2%) of the procedures, respectively. In patients with metastatic PPGL, ablative therapy can effectively achieve local control and palliate symptoms.
format Online
Article
Text
id pubmed-6407137
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64071372019-03-21 Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma Kohlenberg, Jacob Welch, Brian Hamidi, Oksana Callstrom, Matthew Morris, Jonathan Sprung, Juraj Bancos, Irina Young, William Cancers (Basel) Article Metastatic pheochromocytoma and paraganglioma (PPGL) are incurable neuroendocrine tumors. The goals of treatment include palliating symptoms and reducing tumor burden. Little is known about the use of radiofrequency ablation (RFA), cryoablation (CRYO), and percutaneous ethanol injection (PEI) to treat metastatic PPGL. We performed a retrospective study of patients age 17 years and older with metastatic PPGL who were treated with ablative therapy at Mayo Clinic, USA, between June 14, 1999 and November 14, 2017. Our outcomes measures were radiographic response, procedure-related complications, and symptomatic improvement. Thirty-one patients with metastatic PPGL had 123 lesions treated during 42 RFA, 23 CRYO, and 4 PEI procedures. The median duration of follow-up was 60 months (range, 0–163 months) for non-deceased patients. Radiographic local control was achieved in 69/80 (86%) lesions. Improvement in metastasis-related pain or symptoms of catecholamine excess was achieved in 12/13 (92%) procedures. Thirty-three (67%) procedures had no known complications. Clavien-Dindo Grade I, II, IV, and V complications occurred after 7 (14%), 7 (14%), 1 (2%), and 1 (2%) of the procedures, respectively. In patients with metastatic PPGL, ablative therapy can effectively achieve local control and palliate symptoms. MDPI 2019-02-07 /pmc/articles/PMC6407137/ /pubmed/30736463 http://dx.doi.org/10.3390/cancers11020195 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kohlenberg, Jacob
Welch, Brian
Hamidi, Oksana
Callstrom, Matthew
Morris, Jonathan
Sprung, Juraj
Bancos, Irina
Young, William
Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma
title Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma
title_full Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma
title_fullStr Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma
title_full_unstemmed Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma
title_short Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma
title_sort efficacy and safety of ablative therapy in the treatment of patients with metastatic pheochromocytoma and paraganglioma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407137/
https://www.ncbi.nlm.nih.gov/pubmed/30736463
http://dx.doi.org/10.3390/cancers11020195
work_keys_str_mv AT kohlenbergjacob efficacyandsafetyofablativetherapyinthetreatmentofpatientswithmetastaticpheochromocytomaandparaganglioma
AT welchbrian efficacyandsafetyofablativetherapyinthetreatmentofpatientswithmetastaticpheochromocytomaandparaganglioma
AT hamidioksana efficacyandsafetyofablativetherapyinthetreatmentofpatientswithmetastaticpheochromocytomaandparaganglioma
AT callstrommatthew efficacyandsafetyofablativetherapyinthetreatmentofpatientswithmetastaticpheochromocytomaandparaganglioma
AT morrisjonathan efficacyandsafetyofablativetherapyinthetreatmentofpatientswithmetastaticpheochromocytomaandparaganglioma
AT sprungjuraj efficacyandsafetyofablativetherapyinthetreatmentofpatientswithmetastaticpheochromocytomaandparaganglioma
AT bancosirina efficacyandsafetyofablativetherapyinthetreatmentofpatientswithmetastaticpheochromocytomaandparaganglioma
AT youngwilliam efficacyandsafetyofablativetherapyinthetreatmentofpatientswithmetastaticpheochromocytomaandparaganglioma